Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jan;79(2):264–266. doi: 10.1038/sj.bjc.6690043

DNA alkylation and interstrand cross-linking by treosulfan

J A Hartley 1, C C O'Hare 1, J Baumgart 2
PMCID: PMC2362201  PMID: 9888467

Abstract

The anti-tumour drug treosulfan (L-threitol 1,4-bismethanesulphonate, Ovastat) is a prodrug for epoxy compounds by converting non-enzymatically to L-diepoxybutane via the corresponding monoepoxide under physiological conditions. The present study supports the hypothesis that this conversion of treosulfan is required for cytotoxicity in vitro. DNA alkylation and interstrand cross-linking of plasmid DNA is observed after treosulfan treatment, but this is again produced via the epoxide species. Alkylation occurs at guanine bases with a sequence selectivity similar to other alkylating agents such as the nitrogen mustards. In treosulfan-treated K562 cells, cross-links form slowly, reaching a peak at approximately 24 h. Incubation of K562 cells with preformed epoxides shows faster and more efficient DNA cross-linking. © 1999 Cancer Research Campaign

Keywords: treosulfan, DNA cross-linking, DNA alkylation

Full Text

The Full Text of this article is available as a PDF (82.1 KB).


Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES